Table 3.

Secondary efficacy measurements from baseline to week 12. Data were means ± s.d. or medians (interquartile ranges) for skewed variables or numbers (proportions) for categorical variables.

	Sitagliptin (N = 93)	Vildagliptin (N = 94)	Saxagliptin (N = 90)	P* value
BMI (kg/m2) change	−0.5 ± 1.9	−0.1 ± 0.7	0.3 ± 0.8	0.41
TC (mmol/L) change	0.1 (−0.4 to 0.4)	−0.1 (−0.5 to 0.5)	0.5 (0.2–1.0)	0.01
LDL-C (mmol/L) change	−0.2 ± 0.8	−0.2 ± 1.1	0.3 ± 1.1	0.05
HDL-C (mmol/L) change	−0.00 ± 0.2	0.06 ± 0.4	0.02 ± 1.6	0.99
ALT (IU/L) change	0.5 (−1.0 to 5.0)	0.65 (−7.3 to 4.4)	6.0 (0.0–20.2)	0.08
AST (IU/L) change	1.0 (−2.0 to 5.0)	−2.6 (−8.1 to 1.1)	1.5 (−1.0 to 6.2)	0.42
Cr (µmol/L) change	−1.1 ± 9.4	2.3 ± 11.7	−2.8 ± 8.0	0.70
BIL (µmol/L) change	8.1 ± 34.0	1.2 ± 6.7	0.9 ± 5.7	0.42
WBC (109/L) change	−0.2 ± 2.0	−0.3 ± 2.1	0.05 ± 2.1	0.62

P value was calculated for Chi-square test across the three groups. P < 0.05 was considered to be statistically significant.

*Age and HbA1c-adjusted P value.

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Cr, creatine; BIL, total bilirubin; WBC, white blood cell.